Adaptimmune Therapeutics plc
ADAP
$0.2223
$0.00733.40%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -54.88% | 61.37% | 425.03% | -4,781.76% | -63.82% |
| Total Depreciation and Amortization | -1.25% | -2.56% | 22.85% | 53.39% | 99.79% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 455.71% | 161.78% | 113.30% | 35.41% | -52.65% |
| Change in Net Operating Assets | -9.66% | -869.73% | -364.79% | 124.29% | 11.17% |
| Cash from Operations | -133.06% | -20.58% | 208.31% | 14.30% | -818.71% |
| Capital Expenditure | 73.52% | 50.52% | 65.30% | 95.66% | 75.78% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -87.85% | -214.38% | 99.22% | -100.51% | 183.27% |
| Cash from Investing | -88.02% | -215.20% | -127.58% | -100.74% | 225.49% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.65% | -99.83% | -14.29% | 14,815.82% | -94.73% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -98.65% | 4,094.80% | 174,985.71% | 14,815.82% | -94.73% |
| Foreign Exchange rate Adjustments | -151.43% | 65.89% | 89.47% | -170.75% | -92.21% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -148.60% | -840.01% | 272.51% | -129.46% | 86.73% |
